Aktie A2DLUK CATALYST BIOSCIENCES
Zu einer Liste hinzufügen
Um diese Funktionalität nutzen zu können, müssen Sie Mitglied sein
EinloggenRegistrieren

Andere Sprachen Catalyst Biosciences

Aktien

A2DLUK

US14888D2080

CBIO

Markt geschlossen - Nasdaq
Andere Börsenplätze
 22:00:00 02.05.2024 		% 5 Tage % 1. Jan.
14,1 USD +1,73 % Intraday Chart für Catalyst Biosciences -13,64 % +83,85 %
2023 Beijing Continent Pharmaceutical Co., Ltd. hat die Übernahme von Catalyst Biosciences, Inc. (NasdaqCM:CBIO) in einer Reverse-Merger-Transaktion abgeschlossen. CI
2023 Catalyst Biosciences, Inc. meldet Ergebnis für das dritte Quartal und die neun Monate bis zum 30. September 2023 CI

Andere Sprachen

Suchen
Ergebnisse ansehen
Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!
100% kostenlose Registrierung
Catalyst Biosciences : Investor presentation 556.2 KB
Catalyst Biosciences : GNI Group Updates Other Income and Full Year 2023 Consolidated Earnings Forecasts - Form 8-K
Catalyst Biosciences : GNI Group Updates Full Year 2023 Consolidated Earnings Forecast - Form 8-K
Catalyst Biosciences : Change in Certifying Accountants - Form 8-K
Catalyst Biosciences Announces Completion of Business Combination With Beijing Continent Pharmaceuticals and Implementation of Name Change and Reverse Stock Split
Catalyst Biosciences, Inc.(NasdaqCM:CBIO) dropped from NASDAQ Composite Index
Beijing Continent Pharmaceutical Co., Ltd. completed the acquisition of Catalyst Biosciences, Inc. in a reverse merger transaction.
Catalyst Biosciences, Inc. announced that it has received $4.999815 million in funding from GNI USA, Inc.
Catalyst Biosciences, Inc. announced that it expects to receive $4.999815 million in funding from GNI USA, Inc.
Catalyst Biosciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
Catalyst Biosciences, Inc. has Changed its Name to Gyre Therapeutics, Inc
North American Morning Briefing : China Trouble Hits Sentiment
Catalyst Biosciences, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
Catalyst Biosciences Files Registration Statement on Behalf of Selling Stockholders
CATALYST BIOSCIENCES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Catalyst Biosciences, Inc. - CBIO
Catalyst Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023
North American Morning Briefing : Hopes Build for -3-
CATALYST BIOSCIENCES, INC. : Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing (form 8-K)
CATALYST BIOSCIENCES, INC. : Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing (form 8-K)
CATALYST BIOSCIENCES, INC. : Entry into a Material Definitive Agreement, Financial Statements and Exhibits (form 8-K)
Keine Ergebnisse zu dieser Suche
Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Filter

Suchen

Datum der Veröffentlichung

Vom

Bis

  1. Börse
  2. Aktien
  3. A2DLUK Aktie
  4. Nachrichten Catalyst Biosciences
  5. Andere Sprachen